Baseline characteristics and VOD risk factor analysis stratified by age
| . | Total (%) N = 1561 . | Age ≤ 25 y . | Age > 25 y . | ||||
|---|---|---|---|---|---|---|---|
| Total (%) n = 119 . | VOD (%) n = 20 . | P∗ . | Total (%) n = 1442 . | VOD (%) n = 55 . | P∗ . | ||
| Sex | 0.2 | 0.3 | |||||
| Male | 941 (60) | 75 (63) | 15 (20) | 866 (60) | 37 (4) | ||
| Female | 620 (40) | 44 (37) | 5 (11) | 576 (40) | 18 (3) | ||
| BMI | 0.9 | 0.001 | |||||
| ≤20 | 121 (8) | 19 (16) | 3 (16) | 102 (7) | 10 (10) | ||
| >20 | 1440 (92) | 100 (84) | 17 (17) | 1340 (93) | 45 (3) | ||
| Obesity (HCT-CI) | 0.03 | 0.4 | |||||
| Yes | 179 (11) | 17 (14) | 0 (0) | 162 (11) | 5 (3) | ||
| No | 1382 (88) | 102 (86) | 20 (20) | 1280 (89) | 50 (4) | ||
| Diagnosis | |||||||
| AML/MDS | 941 (60) | 51 (43) | 7 (14) | 890 (62) | 30 (3) | ||
| GO | 30 (2) | 3 (3) | 2 (67) | 0.05 | 27 (2) | 4 (15) | 0.01 |
| No GO | 911 (58) | 48 (40) | 5 (10) | 863 (60) | 26 (3) | ||
| ALL | 207 (13) | 44 (37) | 11 (25) | 163 (11) | 7 (4) | ||
| InO | 49 (3) | 15 (13) | 5 (33) | 0.1 | 34 (2) | 2 (6) | 0.9 |
| No InO | 156 (10) | 29 (24) | 6 (21) | 129 (9) | 5 (4) | ||
| CML/MPN | 182 (12) | 2 (2) | 0 (0) | 180 (12) | 10 (6) | ||
| CLL | 59 (4) | 1 (1) | 0 (0) | 58 (4) | 2 (3) | ||
| HD | 20 (1) | 9 (8) | 1 (11) | 11 (1) | 0 (0) | ||
| NHL | 109 (7) | 2 (2) | 0 (0) | 107 (7) | 3 (3) | ||
| MM | 19 (1) | 0 (0) | NA | 19 (1) | 1 (5) | ||
| AA | 17 (1) | 8 (7) | 1 (12) | 9 (1) | 1 (11) | ||
| Sarcoma | 1 (0) | 0 (0) | NA | 1 (0) | 0 (0) | ||
| Other hematological malignancies | 6 (0) | 2 (2) | 0 (0) | 4 (0) | 1 (25) | ||
| HCT-CI | 0.1 | 0.7 | |||||
| ≤ 3 | 994 (64) | 72 (61) | 9 (12) | 922 (64) | 34 (4) | ||
| > 3 | 567 (36) | 47 (39) | 11 (23) | 520 (36) | 21 (4) | ||
| DRI | 0.03 | 0.9 | |||||
| High/very high | 423 (27) | 36 (30) | 11 (31) | 387 (27) | 14 (4) | ||
| Low/intermediate | 981 (63) | 58 (49) | 7 (12) | 923 (64) | 34 (4) | ||
| Missing | 157 (10) | 25 (21) | 2 (8) | 132 (9) | 7 (5) | ||
| Prior lines chemotherapy, n | 0.03 | 0.6 | |||||
| ≤1 | 862 (55) | 47 (39) | 3 (6) | 815 (57) | 29 (4) | ||
| >1 | 699 (45) | 72 (61) | 17 (24) | 627 (43) | 26 (4) | ||
| Diagnosis to TP, mos | |||||||
| ≤12 | 840 (54) | 63 (53) | 7 (11) | 777 (54) | 25 (3) | ||
| >12 | 721 (46) | 56 (47) | 13 (23) | 0.09 | 665 (46) | 30 (4) | 0.2 |
| Donor type | |||||||
| MUD | 747 (48) | 46 (39) | 8 (17) | 701 (49) | 25 (4) | ||
| Haploidentical | 332 (21) | 31 (26) | 7 (23) | 0.6 | 301 (21) | 10 (3) | 0.9 |
| MRD | 436 (28) | 29 (24) | 2 (7) | 0.2 | 407 (28) | 20 (5) | 0.3 |
| CBT | 38 (2) | 13 (11) | 3 (23) | 0.6 | 25 (2) | 0 (0) | NE |
| Other | 8 (1) | 0 (0) | 0 (0) | NE | 8 (1) | 0 (0) | NE |
| Conditioning intensity | |||||||
| MAC | 794 (51) | 67 (56) | 8 (12) | 727 (50) | 29 (4) | ||
| RIC | 767 (49) | 52 (44) | 12 (23) | 0.1 | 715 (50) | 26 (4) | 0.7 |
| MAC: | |||||||
| Busulfan | 756 (48) | 54 (45) | 5 (9) | 702 (49) | 27 (4) | ||
| Other | 38 (2) | 13 (11) | 3 (23) | 0.2 | 25 (2) | 2 (8) | 0.3 |
| RIC: | |||||||
| Busulfan | 36 (2) | 0 (0) | 0 (0) | 36 (2) | 2 (6) | ||
| Melphalan | 661 (42) | 41 (34) | 11 (27) | 620 (43) | 23 (4) | ||
| Other | 70 (4) | 11 (9) | 1 (9) | 0.3 | 59 (4) | 1 (2) | 0.8 |
| Double alkylators | |||||||
| Yes | 301 (19) | 14 (12) | 3 (21) | 287 (20) | 11 (4) | 0.9 | |
| No | 1260 (81) | 105 (88) | 17 (16) | 0.6 | 1155 (80) | 44 (4) | |
| Myeloablative TBI | |||||||
| Yes | 62 (4) | 20 (17) | 5 (25) | 0.3 | 42 (3) | 2 (5) | 0.7 |
| No | 1499 (96) | 99 (83) | 15 (15) | 1400 (97) | 53 (4) | ||
| Stem cell source | |||||||
| Peripheral blood | 1164 (75) | 62 (52) | 12 (19) | 1102 (76) | 47 (4) | ||
| Bone marrow | 359 (23) | 44 (37) | 5 (11) | 0.3 | 315 (22) | 8 (2) | 0.2 |
| Cord blood | 38 (2) | 13 (11) | 3 (23) | 0.8 | 25 (2) | 0 (0) | NA |
| GvHD prophylaxis | 1130 (72) | 60 (50) | 13 (22) | 0.2 | 1070 (74) | 36 (3) | 0.1 |
| PTCy other | 431 (28) | 59 (50) | 7 (12) | 372 (26) | 19 (5) | ||
| Ferritin ng/mL, median | 1280 | 1341 | |||||
| ≤1000 | 647 (41) | 46 (40) | 6 (13) | 601 (42) | 18 (3) | ||
| >1000 | 897 (57) | 70 (60) | 12 (17) | 0.5 | 827 (58) | 36 (4) | 0.2 |
| Bilirubin | |||||||
| WNL | 1457 (93) | 107 (90) | 18 (17) | 1350 (94) | 43 (3) | <0.001 | |
| >ULN to 1.5× ULN | 47 (3) | 3 (3) | 0 (0) | 0.9 | 44 (3) | 6 (14) | |
| >1.5× ULN | 22 (1) | 3 (3) | 1 (33) | 19 (1) | 3 (16) | ||
| ALT | |||||||
| WNL | 980 (63) | 56 (47) | 10 (18) | 924 (64) | 34 (4) | ||
| >ULN to 2.5× ULN | 443 (28) | 40 (34) | 6 (15) | 403 (28) | 11 (3) | ||
| >2.5× ULN | 102 (7) | 16 (13) | 3 (19) | 0.8 | 86 (6) | 7 (8) | 0.02 |
| AST | |||||||
| WNL | 1166 (75) | 75 (63) | 12 (16) | 0.7 | 1091 (76) | 37 (3) | |
| >ULN to 2.5× ULN | 318 (20) | 34 (29) | 7 (21) | 284 (20) | 11 (4) | ||
| >2.5× ULN | 18 (1) | 3 (3) | 0 (0) | 15 (1) | 4 (27) | <0.001 | |
| . | Total (%) N = 1561 . | Age ≤ 25 y . | Age > 25 y . | ||||
|---|---|---|---|---|---|---|---|
| Total (%) n = 119 . | VOD (%) n = 20 . | P∗ . | Total (%) n = 1442 . | VOD (%) n = 55 . | P∗ . | ||
| Sex | 0.2 | 0.3 | |||||
| Male | 941 (60) | 75 (63) | 15 (20) | 866 (60) | 37 (4) | ||
| Female | 620 (40) | 44 (37) | 5 (11) | 576 (40) | 18 (3) | ||
| BMI | 0.9 | 0.001 | |||||
| ≤20 | 121 (8) | 19 (16) | 3 (16) | 102 (7) | 10 (10) | ||
| >20 | 1440 (92) | 100 (84) | 17 (17) | 1340 (93) | 45 (3) | ||
| Obesity (HCT-CI) | 0.03 | 0.4 | |||||
| Yes | 179 (11) | 17 (14) | 0 (0) | 162 (11) | 5 (3) | ||
| No | 1382 (88) | 102 (86) | 20 (20) | 1280 (89) | 50 (4) | ||
| Diagnosis | |||||||
| AML/MDS | 941 (60) | 51 (43) | 7 (14) | 890 (62) | 30 (3) | ||
| GO | 30 (2) | 3 (3) | 2 (67) | 0.05 | 27 (2) | 4 (15) | 0.01 |
| No GO | 911 (58) | 48 (40) | 5 (10) | 863 (60) | 26 (3) | ||
| ALL | 207 (13) | 44 (37) | 11 (25) | 163 (11) | 7 (4) | ||
| InO | 49 (3) | 15 (13) | 5 (33) | 0.1 | 34 (2) | 2 (6) | 0.9 |
| No InO | 156 (10) | 29 (24) | 6 (21) | 129 (9) | 5 (4) | ||
| CML/MPN | 182 (12) | 2 (2) | 0 (0) | 180 (12) | 10 (6) | ||
| CLL | 59 (4) | 1 (1) | 0 (0) | 58 (4) | 2 (3) | ||
| HD | 20 (1) | 9 (8) | 1 (11) | 11 (1) | 0 (0) | ||
| NHL | 109 (7) | 2 (2) | 0 (0) | 107 (7) | 3 (3) | ||
| MM | 19 (1) | 0 (0) | NA | 19 (1) | 1 (5) | ||
| AA | 17 (1) | 8 (7) | 1 (12) | 9 (1) | 1 (11) | ||
| Sarcoma | 1 (0) | 0 (0) | NA | 1 (0) | 0 (0) | ||
| Other hematological malignancies | 6 (0) | 2 (2) | 0 (0) | 4 (0) | 1 (25) | ||
| HCT-CI | 0.1 | 0.7 | |||||
| ≤ 3 | 994 (64) | 72 (61) | 9 (12) | 922 (64) | 34 (4) | ||
| > 3 | 567 (36) | 47 (39) | 11 (23) | 520 (36) | 21 (4) | ||
| DRI | 0.03 | 0.9 | |||||
| High/very high | 423 (27) | 36 (30) | 11 (31) | 387 (27) | 14 (4) | ||
| Low/intermediate | 981 (63) | 58 (49) | 7 (12) | 923 (64) | 34 (4) | ||
| Missing | 157 (10) | 25 (21) | 2 (8) | 132 (9) | 7 (5) | ||
| Prior lines chemotherapy, n | 0.03 | 0.6 | |||||
| ≤1 | 862 (55) | 47 (39) | 3 (6) | 815 (57) | 29 (4) | ||
| >1 | 699 (45) | 72 (61) | 17 (24) | 627 (43) | 26 (4) | ||
| Diagnosis to TP, mos | |||||||
| ≤12 | 840 (54) | 63 (53) | 7 (11) | 777 (54) | 25 (3) | ||
| >12 | 721 (46) | 56 (47) | 13 (23) | 0.09 | 665 (46) | 30 (4) | 0.2 |
| Donor type | |||||||
| MUD | 747 (48) | 46 (39) | 8 (17) | 701 (49) | 25 (4) | ||
| Haploidentical | 332 (21) | 31 (26) | 7 (23) | 0.6 | 301 (21) | 10 (3) | 0.9 |
| MRD | 436 (28) | 29 (24) | 2 (7) | 0.2 | 407 (28) | 20 (5) | 0.3 |
| CBT | 38 (2) | 13 (11) | 3 (23) | 0.6 | 25 (2) | 0 (0) | NE |
| Other | 8 (1) | 0 (0) | 0 (0) | NE | 8 (1) | 0 (0) | NE |
| Conditioning intensity | |||||||
| MAC | 794 (51) | 67 (56) | 8 (12) | 727 (50) | 29 (4) | ||
| RIC | 767 (49) | 52 (44) | 12 (23) | 0.1 | 715 (50) | 26 (4) | 0.7 |
| MAC: | |||||||
| Busulfan | 756 (48) | 54 (45) | 5 (9) | 702 (49) | 27 (4) | ||
| Other | 38 (2) | 13 (11) | 3 (23) | 0.2 | 25 (2) | 2 (8) | 0.3 |
| RIC: | |||||||
| Busulfan | 36 (2) | 0 (0) | 0 (0) | 36 (2) | 2 (6) | ||
| Melphalan | 661 (42) | 41 (34) | 11 (27) | 620 (43) | 23 (4) | ||
| Other | 70 (4) | 11 (9) | 1 (9) | 0.3 | 59 (4) | 1 (2) | 0.8 |
| Double alkylators | |||||||
| Yes | 301 (19) | 14 (12) | 3 (21) | 287 (20) | 11 (4) | 0.9 | |
| No | 1260 (81) | 105 (88) | 17 (16) | 0.6 | 1155 (80) | 44 (4) | |
| Myeloablative TBI | |||||||
| Yes | 62 (4) | 20 (17) | 5 (25) | 0.3 | 42 (3) | 2 (5) | 0.7 |
| No | 1499 (96) | 99 (83) | 15 (15) | 1400 (97) | 53 (4) | ||
| Stem cell source | |||||||
| Peripheral blood | 1164 (75) | 62 (52) | 12 (19) | 1102 (76) | 47 (4) | ||
| Bone marrow | 359 (23) | 44 (37) | 5 (11) | 0.3 | 315 (22) | 8 (2) | 0.2 |
| Cord blood | 38 (2) | 13 (11) | 3 (23) | 0.8 | 25 (2) | 0 (0) | NA |
| GvHD prophylaxis | 1130 (72) | 60 (50) | 13 (22) | 0.2 | 1070 (74) | 36 (3) | 0.1 |
| PTCy other | 431 (28) | 59 (50) | 7 (12) | 372 (26) | 19 (5) | ||
| Ferritin ng/mL, median | 1280 | 1341 | |||||
| ≤1000 | 647 (41) | 46 (40) | 6 (13) | 601 (42) | 18 (3) | ||
| >1000 | 897 (57) | 70 (60) | 12 (17) | 0.5 | 827 (58) | 36 (4) | 0.2 |
| Bilirubin | |||||||
| WNL | 1457 (93) | 107 (90) | 18 (17) | 1350 (94) | 43 (3) | <0.001 | |
| >ULN to 1.5× ULN | 47 (3) | 3 (3) | 0 (0) | 0.9 | 44 (3) | 6 (14) | |
| >1.5× ULN | 22 (1) | 3 (3) | 1 (33) | 19 (1) | 3 (16) | ||
| ALT | |||||||
| WNL | 980 (63) | 56 (47) | 10 (18) | 924 (64) | 34 (4) | ||
| >ULN to 2.5× ULN | 443 (28) | 40 (34) | 6 (15) | 403 (28) | 11 (3) | ||
| >2.5× ULN | 102 (7) | 16 (13) | 3 (19) | 0.8 | 86 (6) | 7 (8) | 0.02 |
| AST | |||||||
| WNL | 1166 (75) | 75 (63) | 12 (16) | 0.7 | 1091 (76) | 37 (3) | |
| >ULN to 2.5× ULN | 318 (20) | 34 (29) | 7 (21) | 284 (20) | 11 (4) | ||
| >2.5× ULN | 18 (1) | 3 (3) | 0 (0) | 15 (1) | 4 (27) | <0.001 | |
Analysis stratified by age: patients aged ≤25 years, and those aged >25 years.
AA, aplastic anemia; ALT, alanine transaminase; AST, aspartate aminotransferase; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BMI, body mass index; CBT, cord blood transplant; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; DRI, disease risk index; GO, gemtuzumab ozogamicin; GVHD, graft-versus-host disease; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; HL, Hodgkin's lymphoma; INO, inotuzumab ozogamicin; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; MM, multiple myeloma; MRD, matched related donor; MUD, matched unrelated donor; NHL, Non-Hodgkin lymphoma; PTCy, posttransplant cyclophosphamide; RIC, reduced-intensity conditioning; TP, transplant; ULN, upper limit of normal; VOD, veno-occlusive disease; WNL, within normal limits.
P values were generated from Fine and Grey regression analysis.